Virinchi Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target
- July 10, 2026
- Posted by: Kashish Aggarwal
- Category: News
Virinchi CMP Rs.16. Market cap Rs.181 Cr. PE Not meaningful. 12-month target Rs.16-18.
Virinchi Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Virinchi shares trading at Rs.16 against a market capitalisation of Rs.181 Cr and a price-to-earnings multiple of Not meaningful. As a healthcare services name on the NSE and BSE, Virinchi enters the Virinchi Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.
Quarterly financials for Virinchi are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Virinchi Q1 Results FY27 result date and cross-check any figures before making investment decisions.
Get Free Investment Predictions and Virinchi Research at Univest
Virinchi (NSE: VIRINCHI) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings ahead of the Virinchi Q1 Results FY27 season, forming the base against which the Virinchi Q1 Results FY27 estimates in this article are built. This Virinchi Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.
Virinchi Q1 FY27 Estimates
| Metric | Detail |
|---|---|
| CMP | Rs.16 |
| Market Cap | Rs.181 Cr |
| Results Date | July-August 2026 (indicative) |
| 12-Month Target (Uniresearch Estimate) | Rs.16-18 |
Univest, a SEBI-Registered Investment Advisor, Tracks Virinchi Ahead of Q1 FY27 Results
Key Catalysts to Watch
1. Occupancy and ARPOB Trends
Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of Virinchi’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Virinchi share price target or faces renewed pressure.
2. Capacity Addition
Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of Virinchi’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Virinchi share price target or faces renewed pressure.
3. Case Mix Improvement
Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of Virinchi’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Virinchi share price target or faces renewed pressure.
Download the Univest iOS App or Univest Android App to track Virinchi’s live price and Q1 FY27 result updates.
Key Risks to the Virinchi Q1 Results FY27 Outlook
- Slower occupancy ramp-up in newly added capacity affecting near-term margins.
- Regulatory changes to pricing or insurance reimbursement norms.
- Talent cost inflation for specialist doctors and clinical staff.
Recent Performance Context
Detailed recent-quarter financials for Virinchi were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.
Technical Analysis Ahead of Virinchi Q1 Results FY27
Virinchi shares last traded at Rs.16. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.
Share Price Target Based on the Virinchi Q1 Results FY27 Outlook
3-6 Month Target
Over a 3-6 month horizon, the Virinchi Q1 Results FY27 trailing-growth framework points to a range of Rs.15-17 for Virinchi, contingent on the Virinchi Q1 Results FY27 print matching or beating the trailing growth trend.
12-Month Target
The 12-month target (Uniresearch estimate) tied to this Virinchi Q1 Results FY27 view for Virinchi works out to Rs.16-18, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Virinchi Q1 Results FY27, not a formal Buy or Sell call.
FY27-28 Outlook
Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Virinchi Q1 Results FY27 analysis would put Virinchi in a Rs.17-19 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.
What to Watch in the Virinchi Q1 Results FY27 Print
- Revenue and PAT versus the Virinchi Q1 Results FY27 estimate range in this preview.
- Management commentary on FY27 growth guidance and margin trajectory relevant to the Virinchi Q1 Results FY27 narrative.
- Occupancy and ARPOB improvement across hospital and diagnostic networks
- Slower occupancy ramp-up in newly added capacity affecting near-term margins
Conclusion on Virinchi Q1 Results FY27
Virinchi enters the Q1 FY27 results season trading at Rs.16, with the 12-month Uniresearch target range of Rs.16-18 reflecting a tracking stance. Investors tracking the Virinchi Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Virinchi Q1 Results FY27
When are Virinchi Q1 FY27 results expected?
Ans. Virinchi’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.
What is the Virinchi Q1 FY27 revenue estimate?
Ans. Detailed quarterly estimates are not available for Virinchi at this time; check Screener.in or the company’s exchange filings for verified numbers.
What is the Virinchi share price target?
Ans. The 12-month Uniresearch estimate for Virinchi share price target is Rs.16-18, based on trailing growth and current valuation multiples.
Is Virinchi a good buy before Q1 FY27 results?
Ans. Virinchi is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.
What should investors watch in Virinchi’s Q1 FY27 results?
Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.
Where can I track Virinchi share price live?
Ans. Virinchi share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.
